Skip to Main Content
Home Books Hematology-Oncology Therapy, 2e

Chapter 9: Colorectal Cancer

Julia Lee Close; Carmen Joseph Allegra

×close section menu
Expand All Sections
Jump to a Section

INTRODUCTION

Epidemiology

Favorite Table | Download (.pdf) | Print
Epidemiology
Incidence
Colon cancer: 96,830 (male: 48,450; female: 48,380. Estimated new cases for 2014 in the United States)
Rectum cancer: 40,000 (male: 23,380; female: 16,620. Estimated new cases for 2014 in the United States) 52.2 per 100,000 male, 39.3 per 100,000 female for colon and rectum cancer
Deaths: Estimated 50,310 in 2014 for colon and rectum cancer (male: 26,270; female: 24,040)
Median age at diagnosis: 69 years
Male to female ratio: 1.7:1

Siegel R et al. CA Cancer J Clin 2014;64:9–29

Surveillance, Epidemiology and End Results (SEER) Program, available from http://seer.cancer.gov (accessed in 2013)
Stage at presentation:
Stage I: 15%
Stage II: 20–30%
Stage III: 30–40%
Stage IV: 20–25%

Skibber JM et al. Cancer of the colon. In: Devita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:1216–1270

Five-Year Survival

Favorite Table | Download (.pdf) | Print
Five-Year Survival
  Colon Rectal
I >90% >90%
II 75-85% 70-85%
IIIA 59% 55%
IIIB 42% 35%
IIIC 27% 24%
IV <5% <5%

A large proportion of colorectal cancer patients are potential candidates for adjuvant therapies for stage II or III disease.

 

AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag, 2002:113–123

Greene FL et al. Ann Surg 2002;236:416–421

Greene FL et al. Proc Am Soc Clin Oncol 2003;22:251 [abstract 1007]

Work-up

Favorite Table | Download (.pdf) | Print
Work-up
In situ and Stage I H&P, carcinoembryonic antigen and (CEA), full colonoscopy, and pathology review
Stage II

H&P, CBC, serum electrolytes, LFTs, serum creatinine, BUN, and CEA. Full colonoscopy, CT scan of thorax and abdomen, and pelvis, pathology review

Rectal lesions: MRI. Determine whether there is a loss of heterozygosity at chromosome 18q and ascertain the presence of microsatellite instability (MSI). Patient at high risk based on loss of heterozygosity at 18q and MSI status can be recommended for adjuvant treatment
Stage III As above for stages I–II. If patient has potentially resectable disease, additional studies may be needed before laparotomy to confirm resectability, including spiral CT scan, contrast MRI, PET scan, angiography, and laparoscopy
Stage IV As above plus KRAS status

de Gramont A et al. Gastrointest Cancer Res 2008,2: S2–S6

 

Skibber JM et al. Cancer of the colon. In: Devita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:1216–1270

Pathology

World Health Organization Classification

  1. Adenocarcinoma (>90%)

  2. Mucinous adenocarcinoma

  3. Adenosquamous carcinoma

  4. Small cell carcinoma

  5. Medullary carcinoma

  6. Signet ring adenocarcinoma

  7. Squamous cell carcinoma

  8. Undifferentiated

 

Skibber JM et al. Cancer of the colon. In: Devita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:1216–1270

Staging

Favorite Table | Download (.pdf) | Print...
New Treatment Regimens
08/30/2018
| New Treatment Regimens
Colorectal Cancer Regimen: Trifluridine/Tipiracil
Hematology-Oncology Therapy
08/30/2018
| New Treatment Regimens
Colorectal Cancer Regimen: Nivolumab
Hematology-Oncology Therapy
08/30/2018
| New Treatment Regimens
Colorectal Cancer Regimen: Pembrolizumab
Hematology-Oncology Therapy

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

This site uses cookies to provide, maintain and improve your experience. MHE Privacy Center Close